Evaluation of Cisplatin-Induced Acute Renal Failure Amelioration Using Fondaparinux and Alteplase

Acute renal failure (ARF) is a deleterious condition with increased mortality or healthcare costs dialysis-dependent end-stage disease. The study aims to compare prophylaxis fondaparinux (Fund) vs. treatment alteplase (Alt) in ameliorating cisplatin (Cis)-induced ARF. Sixty male mice were equally divided randomly into six groups of control, Cis, Alt, and Cis + Alt receiving normal saline for 10 days. All four except the control received (30 mg/kg, i.p.) on day 7, 6 h later, both (0.9 i.v.). animal Fund (5 days, group 7 Cis. euthanized 72 after dose. showed significantly expression levels platelet count, retinoid X receptor alpha (RXR-α) phosphorylated Akt (p-Akt) addition decreased urea, blood urea nitrogen (BUN), uric acid, white cells (WBCs), red (RBCs), relative kidney body weight, injury score, glucose, prothrombin (PT), A Disintegrin And Metalloproteinases-10 (ADAM10), extracellular matrix deposition, protease-activated 2 (PAR-2), fibrinogen when compared Cis-only group. Meanwhile, caspase-3 BUN, WBCs, RBCs, count PT marked decrease PAR-2 protein creatinine found be comparable those results demonstrate that coagulation system’s activation through stimulation due Cis-induced ADAM10 mediated apoptotic pathway, as indicated by p-Akt pathway. This normally accompanied loss RXR-α distal proximal tubules lipid droplets. When animals pre-treated anticoagulant, Fund, previous effect was halted while fibrinolytic agent, most time failed treat toxicity.